Related Experiment Video

Updated: Jun 4, 2026

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector
05:06

Tumor Allotransplantation in Drosophila melanogaster with a Programmable Auto-Nanoliter Injector

Published on: February 2, 2021

Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation

Cristina Cellurale1, Guadalupe Sabio, Norman J Kennedy

  • 1Howard Hughes Medical Institute, Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605, USA.

Molecular and Cellular Biology
|February 2, 2011
PubMed

Insights

The c-Jun NH(2)-terminal kinase (JNK) pathway is crucial for Ras-induced tumor formation. Ablating JNK1 and JNK2 genes prevents Ras-driven cancer development in cells and lung tumors in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • The c-Jun NH(2)-terminal kinase (JNK) pathway regulates gene expression via activating transcription factor (AP1) proteins.
  • JNK signaling is implicated in cell growth and cancer development.
  • Ras proteins are known oncogenes that drive tumor formation.

Purpose of the Study:

  • To investigate the role of JNK signaling in Ras-induced tumor formation.
  • To determine if JNK is essential for oncogenic Ras-driven cellular transformation and tumor development.

Main Methods:

  • Compound ablation of JNK1 and JNK2 genes in primary cells.
  • Assessing Ras-induced transformation in p53-deficient cells in vitro.
  • Analyzing lung tumor development in vivo following KRas gene activation.

Main Results:

  • JNK signaling is required for the transformation of p53-deficient primary cells induced by Ras.
  • Complete ablation of JNK1 and JNK2 prevents the development of lung tumors driven by activated KRas.
  • These findings highlight JNK's essential role in Ras-mediated tumorigenesis.

Conclusions:

  • JNK is a critical mediator of Ras-induced tumorigenesis.
  • Targeting the JNK pathway may offer a therapeutic strategy for cancers driven by Ras mutations.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...